Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ADP063-ABC
- Development stage
- Unknown
- Lead developer
- Alector
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
ADP063-ABC is a preclinical therapeutic candidate developed by Alector for the treatment of neurodegenerative diseases such as Alzheimer's disease and frontotemporal dementia. It combines a proprietary anti-tau monoclonal antibody with Alector's ABC (Alector Brain Carrier) technology and an optimized antibody constant region. The drug is designed to block the spread of tau aggregates in the brain—a key pathological feature in several neurodegenerative disorders—and has potential for subcutaneous delivery. By targeting tau pathology, it aims to slow cognitive decline associated with these diseases[1][2][3][4][7].
02
Targets
MAPT (Microtubule-associated protein tau)
Beyond the preview
Go deeper on ADP063-ABC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ADP063-ABC.